About NANOVIRICIDES, INC.
NanoViricides is a biotechnology company developing broad-spectrum nanoviricides to combat various viral diseases, including MPox, Ebola, and others. The company is currently conducting Phase II clinical trials for NV-387 in the Democratic Republic of Congo.
Development of broad-spectrum nanoviricides targeting up to 90-95% of known virusesCreation of nanoviricides for diseases such as RSV, COVID-19, Flu, Smallpox, Shingles, Dengue, Rabies, Ebola, and MPoxConducting Phase II clinical trials for NV-387 for MPox and potential Ebola treatment
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to NANOVIRICIDES, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.